VX 497

Known as: VX-497 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2018
01220002018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
VX-497 is a poorly water-soluble compound. It is formulated in PEG-400 and encapsulated in softgel capsules. Although the drug… (More)
Is this relevant?
2005
2005
Inhibition of inosine monophosphate dehydrogenase (IMPDH) is one of several proposed mechanisms of action for ribavirin (RBV), a… (More)
Is this relevant?
2004
2004
The enzyme inosine monophosphate dehydrogenase (IMPDH) catalyzes the rate-limiting step in the de novo biosynthesis of guanine… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
The recent development of in vitro hepatitis C virus (HCV) RNA replication systems has provided useful tools for studying the… (More)
Is this relevant?
2002
2002
Inosine 5'-monophosphate dehydrogenase (IMPDH) enzyme catalyzes the rate-limiting step in the de novo biosynthesis of guanine… (More)
Is this relevant?
Review
2002
Review
2002
Potent inhibitors of enzymes catalyzing reactions in the de novo pathways for biosynthesis of purine and pyrimidine nucleotides… (More)
Is this relevant?
2001
2001
Inosine monophosphate dehydrogenase (IMPDH) is an essential rate-limiting enzyme in the purine metabolic pathway, catalyzing the… (More)
Is this relevant?
2001
2001
VX-497 is the first inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor generated in a structure-based drug design program… (More)
Is this relevant?
Review
2001
Review
2001
With the exception of organ transplant immunosuppression, the treatment of various IMPDH-dependent hyperproliferative diseases by… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
The enzyme IMP dehydrogenase (IMPDH) catalyzes an essential step in the de novo biosynthesis of guanine nucleotides, namely, the… (More)
Is this relevant?